At the 4-week follow-up assessment after completing treatment, the CBL-514 group had lost >200 mL more fat on average than the placebo group (highly significant LS mean treatment difference), and this difference was maintained until the 8-week follow-up (ITT population).
← all excerpts
Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.
1
—
—